×
About 27,783 results

ALLMedicine™ Systemic Lupus Erythematosus Center

Research & Reviews  9,619 results

Proportion of B cell subsets and Nrf2 mediated redox regulation in systemic lupus eryth...
https://doi.org/10.1016/j.imbio.2022.152180
Immunobiology Gautam P, Kaushal J et. al.

Jan 16th, 2022 - Systemic lupus erythematosus (SLE) is characterized by expansion of autoreactive lymphocytes and impaired management of oxidative stress. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) plays a significant role in maintaining the redox homeosta...

Cardiovascular Outcomes in Systemic Lupus Erythematosus.
https://doi.org/10.1007/s11886-021-01626-9 10.1177/0961203319888691 10.1038/s41584-021-00668-1 10.1093/rheumatology/keu412 10.1002/art.41392 10.1016/j.jacc.2021.02.029 10.1177/0961203318786436 10.1016/j.autrev.2020.102531 10.1016/j.lpm.2008.08.010 10.1093/qjmed/hcx195 10.1177/0961203318770018 10.3899/jrheum.160493 10.4103/0366-6999.166029 10.1016/j.amjmed.2007.01.024 10.1161/CIRCULATIONAHA.111.028522 10.3899/jrheum.150451 10.1093/aje/kws130 10.1002/acr.23018 10.1136/rmdopen-2020-001247 10.1016/j.amjcard.2018.09.043 10.1136/annrheumdis-2015-207719 10.1016/j.ijcard.2007.01.117 10.1177/0961203313497416 10.1002/acr.23509 10.1136/annrheumdis-2016-210973 10.1097/BOR.0000000000000480 10.1002/art.23816 10.1002/acr.20122 10.1136/heartjnl-2016-309561 10.3899/jrheum.190502 10.1002/acr.23880 10.1002/art.24537 10.1177/0961203307081113 10.1002/art.23353 10.1016/j.semarthrit.2012.12.002 10.3899/jrheum.161121 10.1177/0961203311425524 10.1016/0002-9343(92)90578-y 10.1155/2017/9680729 10.3109/08916934.2014.983264 10.1093/rheumatology/kew475 10.1093/rheumatology/kez239 10.1136/annrheumdis-2013-204838 10.1136/lupus-2020-000448 10.3899/jrheum.150983 10.1016/j.jaad.2020.12.013 10.1177/0961203317722847 10.1016/j.autrev.2014.10.019 10.1007/s10067-018-4286-9
Current Cardiology Reports; Sairam S, Sureen A et. al.

Jan 15th, 2022 - To review cardiovascular outcomes (CVE) in systemic lupus erythematosus (SLE) that evolves over time. Inception cohorts now report long-term data, and large population registries add to our knowledge. Mortality and cardiovascular morbidity remain ...

Identification of common susceptibility genes and drug target genes in multiple scleros...
https://doi.org/10.1016/j.msard.2022.103504
Multiple Sclerosis and Related Disorders; Liu Y, Rang X et. al.

Jan 15th, 2022 - Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease of the white matter in the central nervous system (CNS). In clinical practice, it was found that MS is associated with a variety of autoimmune diseases, such as systemic lupus...

see more →

Guidelines  11 results

The significance of the low sex ratios of offspring and of sibs of probands with system...
https://doi.org/10.1016/j.earlhumdev.2019.104871
Early Human Development; James WH, Grech V

Sep 8th, 2019 - There is good evidence that there are significantly low sex ratios (proportions male) in the offspring of patients with some immune diseases e.g. systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). There is also strong evidence that ...

2019 update of the EULAR recommendations for the management of systemic lupus erythemat...
https://doi.org/10.1136/annrheumdis-2019-215089
Annals of the Rheumatic Diseases; Fanouriakis A, Kostopoulou M et. al.

Mar 31st, 2019 - Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to f...

First Latin American clinical practice guidelines for the treatment of systemic lupus e...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225798
Annals of the Rheumatic Diseases; Pons-Estel BA, Bonfa E et. al.

Jul 27th, 2018 - Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therap...

The British Society for Rheumatology guideline for the management of systemic lupus ery...
https://doi.org/10.1093/rheumatology/kex291
Rheumatology (Oxford, England); Gordon C, Amissah-Arthur MB et. al.

Oct 14th, 2017 - The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary.|2017|Gordon C,Amissah-Arthur MB,Gayed M,Brown S,Bruce IN,|diagnosis,immunology,therapy,

The British Society for Rheumatology guideline for the management of systemic lupus ery...
https://doi.org/10.1093/rheumatology/kex286
Rheumatology (Oxford, England); Gordon C, Amissah-Arthur MB et. al.

Oct 14th, 2017 - The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults.|2017|Gordon C,Amissah-Arthur MB,Gayed M,Brown S,Bruce IN,|diagnosis,therapy,standards,standards,

see more →

Drugs  300 results see all →

Clinicaltrials.gov  227 results

A Study Evaluating the Efficacy and Safety of BMS-986256 Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
https://clinicaltrials.gov/ct2/show/NCT04895696

Jan 14th, 2022 - The purpose of this study is to evaluate the effectiveness, safety and tolerability of BMS-986256 in participants with active SLE.

A Model About the Response of Belimumab in SLE
https://clinicaltrials.gov/ct2/show/NCT04893161

Jan 14th, 2022 - Preamble: Belimumab is an inhibitor of B cell activating factor (BAFF) that has been developed as an agent for the treatment of patients with systemic lupus erythematosus (SLE). In July 2019, belimumab was approved for marketing in China. The beli...

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
https://clinicaltrials.gov/ct2/show/NCT04680637

Jan 13th, 2022 - The primary objective is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.

Safety and Immunogenicity of Sars-cov-2 Vaccine in Patients With Rheumatic Diseases
https://clinicaltrials.gov/ct2/show/NCT05191368

Jan 13th, 2022 - Rheumatic diseases (RDS) are a large class of systemic diseases caused by genetic background, environment and physics, infection, metabolism, endocrine, immune response and other reasons, mainly involving joints and surrounding tissues. The diseas...

Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
https://clinicaltrials.gov/ct2/show/NCT00055055

Jan 12th, 2022 - Most autoimmune diseases are thought to develop as a result of chronic immune activation and dysregulation after selected environmental exposures in genetically susceptible individuals. Current evidence suggests that the adult and juvenile forms o...

see more →

News  946 results

Shorter Course of Anticoagulant Therapy Adequate for Provoked VTE in Children
https://www.medscape.com/viewarticle/966398

Jan 12th, 2022 - NEW YORK (Reuters Health) - For children with acute provoked venous thromboembolism (VTE), six weeks of anticoagulant therapy is as effective as a three-month course of anticoagulant therapy, results of a new clinical trial suggest. "When treatmen...

Top 10 Take-home Messages From the 2018 ACC/AHA Cholesterol Guidelines
https://www.medscape.com/viewarticle/958747

Dec 15th, 2021 - This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to Medscape's InDiscussion series on dyslipidemia. This is episode four, "The Top 10 Take-Home Messages From the 2018 ACC/AHA Cholesterol Guidelines." Today we are fortuna...

Adding Rituximab to Belimumab Offers No Help for Lupus
https://www.medscape.com/viewarticle/962939

Nov 15th, 2021 - Adding a single cycle of rituximab to belimumab (Benlysta) did not improve disease control for patients with systemic lupus erythematosus (SLE) in comparison with belimumab alone in a phase 3 randomized, controlled trial. Among patients with SLE w...

COVID Vaccine Response Found Mostly Robust in RA, SLE Patients
https://www.medscape.com/viewarticle/962782

Nov 11th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Dr Ines Colmegna Immunosuppressed patients with autoimmune diseases who received the Moderna mRNA-1273 SARS-CoV-2 two-dose vaccine series had a fr...

Lupus patients in remission see more flares with HCQ reduction, discontinuation
https://www.mdedge.com/rheumatology/article/248448/lupus-connective-tissue-diseases/lupus-patients-remission-see-more
Tara Haelle

Nov 9th, 2021 - Continuation of hydroxychloroquine (HCQ) when a patient’s systemic lupus erythematosus (SLE) is in remission or has very low disease activity is linked to a lower risk of flares than is reducing or stopping the antimalarial drug, according to new.

see more →

Patient Education  10 results see all →